Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Local adverse effects of steroid use and the burning sensation of calcineurin inhibitors impair patients’ adherence to treatment and decrease the treatment response in atopic dermatitis (AD). Steroid phobia appears to be a psychological problem in patients with AD. Topical non-steroidal remedies are in demand. Areas covered: This manuscript reviews the current literature on preclinical and clinical studies regarding topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor. We also discuss the mechanistic background of E6005/RVT-501 in the treatment of AD. Expert opinion: Topical E6005/RVT-501 improves skin eruption and pruritus of pediatric and adult AD patients without any serious side effects. It is useful for mild to moderate lesions of AD in pediatric and adult patients. Topical E6005/RVT-501 is non-steroidal agent but its potency is equal to that of mild rank topical steroid, therefore, it may fit the demand of patients with steroid phobia. Its steroid-sparing effects may also be investigated in future clinical trials and may minimize the dose and frequency of topical steroids.

Original languageEnglish
Pages (from-to)1403-1408
Number of pages6
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number12
DOIs
Publication statusPublished - Dec 2 2017

Fingerprint

Phosphodiesterase 4 Inhibitors
Atopic Dermatitis
Steroids
Phobic Disorders
Therapeutics
Pediatrics
Expert Testimony
Pruritus
Patient Compliance
methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate
Clinical Trials
Psychology
Skin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{77577d8b1d8c43c4bebb79a97fad5772,
title = "Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis",
abstract = "Introduction: Local adverse effects of steroid use and the burning sensation of calcineurin inhibitors impair patients’ adherence to treatment and decrease the treatment response in atopic dermatitis (AD). Steroid phobia appears to be a psychological problem in patients with AD. Topical non-steroidal remedies are in demand. Areas covered: This manuscript reviews the current literature on preclinical and clinical studies regarding topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor. We also discuss the mechanistic background of E6005/RVT-501 in the treatment of AD. Expert opinion: Topical E6005/RVT-501 improves skin eruption and pruritus of pediatric and adult AD patients without any serious side effects. It is useful for mild to moderate lesions of AD in pediatric and adult patients. Topical E6005/RVT-501 is non-steroidal agent but its potency is equal to that of mild rank topical steroid, therefore, it may fit the demand of patients with steroid phobia. Its steroid-sparing effects may also be investigated in future clinical trials and may minimize the dose and frequency of topical steroids.",
author = "Masutaka Furue and Takafumi Kadono and Gaku Tsuji and Takeshi Nakahara",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/13543784.2017.1397626",
language = "English",
volume = "26",
pages = "1403--1408",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis

AU - Furue, Masutaka

AU - Kadono, Takafumi

AU - Tsuji, Gaku

AU - Nakahara, Takeshi

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Introduction: Local adverse effects of steroid use and the burning sensation of calcineurin inhibitors impair patients’ adherence to treatment and decrease the treatment response in atopic dermatitis (AD). Steroid phobia appears to be a psychological problem in patients with AD. Topical non-steroidal remedies are in demand. Areas covered: This manuscript reviews the current literature on preclinical and clinical studies regarding topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor. We also discuss the mechanistic background of E6005/RVT-501 in the treatment of AD. Expert opinion: Topical E6005/RVT-501 improves skin eruption and pruritus of pediatric and adult AD patients without any serious side effects. It is useful for mild to moderate lesions of AD in pediatric and adult patients. Topical E6005/RVT-501 is non-steroidal agent but its potency is equal to that of mild rank topical steroid, therefore, it may fit the demand of patients with steroid phobia. Its steroid-sparing effects may also be investigated in future clinical trials and may minimize the dose and frequency of topical steroids.

AB - Introduction: Local adverse effects of steroid use and the burning sensation of calcineurin inhibitors impair patients’ adherence to treatment and decrease the treatment response in atopic dermatitis (AD). Steroid phobia appears to be a psychological problem in patients with AD. Topical non-steroidal remedies are in demand. Areas covered: This manuscript reviews the current literature on preclinical and clinical studies regarding topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor. We also discuss the mechanistic background of E6005/RVT-501 in the treatment of AD. Expert opinion: Topical E6005/RVT-501 improves skin eruption and pruritus of pediatric and adult AD patients without any serious side effects. It is useful for mild to moderate lesions of AD in pediatric and adult patients. Topical E6005/RVT-501 is non-steroidal agent but its potency is equal to that of mild rank topical steroid, therefore, it may fit the demand of patients with steroid phobia. Its steroid-sparing effects may also be investigated in future clinical trials and may minimize the dose and frequency of topical steroids.

UR - http://www.scopus.com/inward/record.url?scp=85032711247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032711247&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1397626

DO - 10.1080/13543784.2017.1397626

M3 - Article

C2 - 29068253

AN - SCOPUS:85032711247

VL - 26

SP - 1403

EP - 1408

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -